Cost Utility Analysis of Everolimus in the Treatment of Metastatic Renal Cell Cancer in the Netherlands

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.534
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness and Cost-Utility Analysis of Sunitinib Versus Sorafenib and Bevacizumab + Interferon-Alfa as First-Line Treatment for Metastatic Renal Cell Carcinoma in Ecuador

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Pcn27 - The Real-World Cost and Effectiveness of Everolimus in Metastatic Breast Cancer in the Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Everolimus &Ndash; A New Approach in the Treatment of Renal Cell Carcinoma

Cancer Management and Research
Oncology
2010English

Cost-Effectiveness Analysis of LHRH Agonists in the Treatment of Metastatic Prostate Cancer in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Cost-Utility Analysis of Cancer Prevention, Treatment, and Control

American Journal of Preventive Medicine
EpidemiologyPublic HealthOccupational HealthEnvironmental
2016English

Cost Effectiveness of Renal Denervation Therapy for the Treatment of Resistant Hypertension in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy